Biogen acquires Apellis Pharmaceuticals

Biogen agreed to acquire Apellis Pharmaceuticals. Reported deal value: $5.6B. Status: Announced. Sector: biotechnology. Target headquarters context: Waltham, Massachusetts, United States.

This page summarizes publicly available information about the transaction as of 2026-05-14. Figures and status may change as filings and press coverage update.

Biogen Completes Apellis Acquisition to Expand Rare Disease and Nephrology Portfolio May 14, 2026 has completed its acquisition of Apellis Pharmaceuticals , adding two commercial complement-targeting therapies and expanding the biotechnology company presence in nephrology and rare disease markets as it seeks new growth drivers beyond its traditional neuroscience business